T1	Disorder 0 14	Liver toxicity
N1 	Reference T1 UMLS:C0348754	Liver toxicity
T2	Pharmacological_substance 22 34	temozolomide
N1000 	Reference T2 MeSH:C047246	temozolomide
T3	Disorder 143 159	malignant glioma
N2 	Reference T3 UMLS:C0555198	malignant glioma
T4	Pharmacological_substance 278 290	temozolomide
N1001 	Reference T4 MeSH:C047246	temozolomide
T5	Disorder 328 342	liver toxicity
N3 	Reference T5 UMLS:C0348754	liver toxicity
T6	Disorder 348 356	jaundice
N4 	Reference T6 UMLS:C0022346	jaundice
T7	Pharmacological_substance 387 399	temozolomide
N1002 	Reference T7 MeSH:C047246	temozolomide
T8	Disorder 482 494	glioblastoma
N5 	Reference T8 UMLS:C0017636	glioblastoma
T9	Disorder 602 619	tumor progression
N6 	Reference T9 UMLS:C0178874	tumor progression
T10	Pharmacological_substance 651 663	temozolomide
N1003 	Reference T10 MeSH:C047246	temozolomide
T11	Disorder 685 693	toxicity
N7 	Reference T11 UMLS:C0600688	toxicity
T12	Pharmacological_substance 751 762	bevacizumab
N1004 	Reference T12 MeSH:D000068258	bevacizumab
T13	Pharmacological_substance 767 777	irinotecan
N1005 	Reference T13 MeSH:C051890	irinotecan
T14	Disorder 803 817	liver toxicity
N8 	Reference T14 UMLS:C0348754	liver toxicity
T15	Disorder 862 870	toxicity
N9 	Reference T15 UMLS:C0600688	toxicity
T16	Disorder 876 884	jaundice
N10 	Reference T16 UMLS:C0022346	jaundice
T17	Pharmacological_substance 959 971	temozolomide
N1006 	Reference T17 MeSH:C047246	temozolomide
T22	Combination 726 737	combination
T26	Pharmacological_substance 202 220	alternative agents
T28	Speculation_cue 889 897	probably
T34	Negation_cue 800 802	no
T18	Manner_cue 321 327	severe
T23	Negation_cue 677 684	without
